Chief Medical Officer and Senior Vice President of Global Medical at Amgen, John Tsai, MD, is moving to Novartis to act as their new CMO and Head of Global Drug Development (GDD). He is filling a role that was vacated when Dr Vas Narasimhan became CEO of the company in February and will start in his new position at the beginning of May.

“I am delighted to welcome John to Novartis,” said Dr. Narasimhan in a statement. “As we continue to reimagine drug development, his expertise across multiple therapeutic areas, including cardiovascular, oncology and neuroscience combined with his background in electrical engineering will be a source of great strength for Novartis. John has a great track record in nurturing talent across clinical development, medical affairs and development operations and shares our commitment to build an empowered and inspired organization. I also want to express my sincere gratitude to Rob Kowalski for his excellent ad interim leadership of the GDD organization.”

Dr Tsai began his current role at Amgen in May 2017 and has been responsible for overseeing all clinical and medical functions across many sites around the world. Prior to this, he had spent 11 years at Bristol-Myers Squibb, serving as the Global Head of Clinical Development. At Novartis, his role will include moving the company’s medicines and biosimilars pipeline forwards, as well as leading an on-going renovation of the GDD organisation to enable more agile drug development.

“I feel honoured to have the opportunity to lead the Novartis Global Drug Development organization and do my part in bringing forward the company’s strong pipeline of medicines that address some of humanity’s biggest health challenges,” said Dr Tsai. “I am also excited to work with my colleagues at Novartis to pioneer novel paradigms for drug development with data and digital technologies at the core.”

More on these topics